Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Allergan : Receives Refusal to File Letter from FDA for Vraylar® cariprazine Supplemental New Drug Application sNDA for the Treatment of Negative...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:46pm CEST

Allergan Receives Refusal to File Letter from FDA for Vraylar® cariprazine Supplemental New Drug Application sNDA for the Treatment of Negative Symptoms in Schizophrenia

By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Allergan plc (NYSE: AGN) announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral, once daily atypical antipsychotic approved in the United States for the treatment of schizophrenia and the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder (see also Allergan plc).

Upon its preliminary review, FDA determined that the sNDA for treatment of negative symptoms was not sufficiently complete to permit a substantive review.

"We are disappointed with the FDA decision on our submission. We will request a meeting with FDA to discuss and determine our next steps. Vraylar is an important treatment option for patients suffering from bipolar I disorder and schizophrenia. We remain committed to our mental health program and to cariprazine and its potential as a treatment option for patients suffering from negative symptoms associated with schizophrenia," said David Nicholson Ph.D., Chief Research & Development Officer, Allergan.

Schizophrenia is a chronic and disabling disorder that includes positive symptoms (i.e. hallucinations, delusions and thought disorders) and negative symptoms (i.e. loss of motivation and social withdrawal). These symptoms are strongly associated with long term morbidity, poor psychosocial functioning and considerable social and economic costs.

Cariprazine is approved in Europe for the treatment of schizophrenia. The approval includes data from the 460-patient negative symptoms study which was conducted by Gedeon Richter and published in the Lancet on February 6, 2017.

The Company will seek immediate guidance, and is in the process of planning a meeting with the FDA, to respond to the issues, and to seek clarification of what additional information will be required.

Keywords for this news article include: Psychiatry, FDA Actions, Allergan plc, Schizophrenia, Mental Health Diseases and Conditions, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
12:46a ALLERGAN : Issues Investor FAQ on Federal District Court RESTASIS® Patent Decisi..
10/18 ALLERGAN : ruling casts doubt on tribal patent strategy
10/18 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/18 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/17 Amneal, Impax combine to tackle generic drug pricing pressure
10/16DJALLERGAN : Loses Patent Fight in Federal Court
10/16 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/16 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/16 ALLERGAN : Announces Settlement on RESTASIS 0.05% Patent Litigation with InnoPha..
10/13 ALLERGAN : to Present Data from More Than 20 Abstracts at the 2017 Fall Clinical..
More news
News from SeekingAlpha
12:18a J&J : Unattractive
10/18 Generic Restasis Risk Metastasizes To Shire
10/18 Shire feels Amgen's Restasis patent pain, shares down 3%
10/18 ALLERGAN : This Pharma Darling Faces Uncertainty Too
10/17 Syndax in-licenses blood cancer candidates from Vitae Pharma
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 621 M
Net income 2017 -3 982 M
Debt 2017 24 536 M
Yield 2017 1,56%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,48x
EV / Sales 2018 5,15x
Capitalization 62 565 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 255 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-10.89%62 565
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423